Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Has Average Price Target of $28.94 According to Analysts

Posted by Brian Himes on Oct 15th, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eight analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $30.06.

ADPT has been the topic of several research reports. National Bank Financial set a $34.00 price target on Adaptive Biotechnologies in a research report on Tuesday, September 22nd. Morgan Stanley increased their price objective on Adaptive Biotechnologies from $22.00 to $27.00 and gave the stock an “equal weight” rating in a report on Monday. Piper Sandler raised their price objective on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Guggenheim boosted their target price on shares of Adaptive Biotechnologies from $25.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Finally, BTIG Research boosted their target price on shares of Adaptive Biotechnologies from $25.00 to $34.00 and gave the company a “buy” rating in a report on Tuesday, September 22nd.

View Our Latest Stock Analysis on Adaptive Biotechnologies

Insider Transactions at Adaptive Biotechnologies

In related news, insider Susan Bobulsky sold 6,444 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $30.00, for a total value of $193,320.00. Following the sale, the insider owned 389,350 shares in the company, valued at $11,680,500. This represents a 1.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Francis Lo sold 26,792 shares of the firm’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $28.28, for a total value of $757,677.76. Following the transaction, the insider owned 220,867 shares of the company’s stock, valued at $6,246,118.76. The trade was a 10.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 1,449,414 shares of company stock worth $35,160,168. Company insiders own 5.70% of the company’s stock.

Institutional Trading of Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently bought and sold shares of ADPT. BlackRock Inc. purchased a new position in shares of Adaptive Biotechnologies in the second quarter worth $324,735,000. Wellington Management Group LLP boosted its position in shares of Adaptive Biotechnologies by 53.2% during the second quarter. Wellington Management Group LLP now owns 5,911,366 shares of the company’s stock valued at $126,799,000 after buying an additional 2,053,944 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Adaptive Biotechnologies during the second quarter valued at $37,109,000. Capricorn Fund Managers Ltd purchased a new stake in shares of Adaptive Biotechnologies during the first quarter valued at $17,930,000. Finally, Freestone Grove Partners LP purchased a new stake in shares of Adaptive Biotechnologies during the second quarter valued at $18,912,000. 99.17% of the stock is currently owned by institutional investors.

Adaptive Biotechnologies Stock Performance

Shares of ADPT stock opened at $25.62 on Monday. The stock has a fifty day moving average of $26.14 and a 200 day moving average of $20.36. Adaptive Biotechnologies has a 52 week low of $12.00 and a 52 week high of $30.74. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22. The firm has a market capitalization of $4.09 billion, a price-to-earnings ratio of -62.49 and a beta of 2.09.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last announced its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The company had revenue of $71.55 million for the quarter, compared to the consensus estimate of $65.44 million. During the same period in the previous year, the firm posted ($0.17) EPS. The company’s revenue for the quarter was up 21.5% on a year-over-year basis. As a group, research analysts expect that Adaptive Biotechnologies will post -0.40 earnings per share for the current year.

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and therapeutic applications. Its technologies analyze immune-cell receptors, including T-cell and B-cell receptors, to help identify and measure immune responses associated with cancer, infectious diseases and other conditions.

The company’s product portfolio includes immunoSEQ, a research and clinical platform for immune-repertoire sequencing, and clonoSEQ, a diagnostic test used to detect and monitor measurable residual disease in certain blood cancers.

Analyst Recommendations for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.